drugset / Trial / NCT03709355

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

NCT03709355

Phase 1 Completed 56 enrolled Viriom
RandomizedFactorialOpen-labelTreatment

Summary

The study assesses PK and safety of other drugs, such as some antibiotics, proton pump inhibitors, statins, and combined oral contraceptives when co-administered with Elpida®

Timeline

Start
2018-11-14
Primary completion
2019-09-06
Completion
2019-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 80 mg
Subject Clarithromycin Small molecule 250 mg
Subject Elsulfavirine Small molecule 20 mg
Subject Levonorgestrel Small molecule 150 ug
Subject Omeprazole Other / unclassified 20 mg
Subject Rifabutin Small molecule 150 mg
Subject Rifampin Small molecule 150 mg
Subject ethinyl estradiol Small molecule 30 ug